ProQR Therapeutics (NASDAQ:PRQR) had its target price lowered by Chardan Capital from $25.00 to $20.00 in a report released on Tuesday, BenzingaRatingsTable reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Several other analysts have also weighed in on the company. HC Wainwright reissued a buy rating and issued a $20.00 target price on shares of ProQR Therapeutics in a report on Tuesday, July 21st. Zacks Investment Research raised ProQR Therapeutics from a hold rating to a buy rating and set a $6.00 target price on the stock in a report on Saturday, May 9th. Finally, BidaskClub lowered ProQR Therapeutics from a hold rating to a sell rating in a report on Tuesday, July 7th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. ProQR Therapeutics has a consensus rating of Buy and a consensus target price of $21.50.
NASDAQ:PRQR traded up $0.09 during trading hours on Tuesday, hitting $5.34. The company’s stock had a trading volume of 1,260 shares, compared to its average volume of 187,784. The business’s 50-day moving average is $5.37 and its two-hundred day moving average is $6.02. The company has a market capitalization of $285.07 million, a PE ratio of -4.34 and a beta of 0.45. The company has a debt-to-equity ratio of 0.06, a quick ratio of 10.09 and a current ratio of 10.09. ProQR Therapeutics has a 52-week low of $4.46 and a 52-week high of $10.98.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. RTW Investments LP boosted its stake in shares of ProQR Therapeutics by 2.6% during the second quarter. RTW Investments LP now owns 4,902,785 shares of the biopharmaceutical company’s stock valued at $29,809,000 after acquiring an additional 123,650 shares during the last quarter. Jennison Associates LLC boosted its stake in ProQR Therapeutics by 0.5% in the 2nd quarter. Jennison Associates LLC now owns 2,625,514 shares of the biopharmaceutical company’s stock worth $15,963,000 after buying an additional 13,208 shares during the last quarter. DAFNA Capital Management LLC boosted its stake in ProQR Therapeutics by 11.1% in the 1st quarter. DAFNA Capital Management LLC now owns 1,237,400 shares of the biopharmaceutical company’s stock worth $6,793,000 after buying an additional 123,400 shares during the last quarter. Kerrisdale Advisers LLC boosted its stake in ProQR Therapeutics by 1.2% in the 2nd quarter. Kerrisdale Advisers LLC now owns 453,182 shares of the biopharmaceutical company’s stock worth $2,755,000 after buying an additional 5,525 shares during the last quarter. Finally, Cowen AND Company LLC boosted its stake in ProQR Therapeutics by 242.1% in the 1st quarter. Cowen AND Company LLC now owns 354,849 shares of the biopharmaceutical company’s stock worth $1,948,000 after buying an additional 251,122 shares during the last quarter. 58.98% of the stock is currently owned by institutional investors and hedge funds.
ProQR Therapeutics Company Profile
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
Read More: What is a dead cat bounce?
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.